The antibody response was impaired while B cells were depleted, but T-cell response appeared to be present.
Studies have shown reduced vaccine responses in patients receiving any of several multiple sclerosis (MS) disease-modifying therapies (DMTs), such as anti-CD20s and sphingosine-1-phosphate modulators. In this study, investigators evaluated humoral and cellular immune responses to SARS-CoV-2 vaccination in 82 patients with MS or other neuroimmune diseases receiving anti-CD20 therapy and 82 age- and sex-matched controls who contributed blood samples 14 to 21 days after the first vaccination and 21 to 28 days after the second vaccination.
At baseline, 3 patients and 1 healthy participant had antibodies against the SARS-CoV-2 spike. After the second vaccination, all healthy controls developed antibodies, as did 70% of anti-CD20 treated patients.…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)